Search





Search





Markets
/
Stocks
/
lxeo
/

Lexeo Therapeutics Inc

LXEO

Add to Watchlist

4.480USD

-0.180-3.86%

Close 07-27 16:00（ET）Quotes delayed by 15 min

331.89MMarket Cap

LossP/E TTM

Lexeo Therapeutics Inc

4.480

-0.180-3.86%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

LXEO Cash Flow Statement

You can access the annual and quarterly cash flow statements of Lexeo Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

2.63%-21.14M

29.11%-20.08M

-65.94%-29.55M

-35.07%-27.22M

-46.07%-21.72M

-102.60%-28.33M

-27.65%-17.81M

-52.77%-20.15M

19.09%-14.87M

15.91%-13.98M

-18.32%-13.95M

-19.37%-13.19M

-21.73%-18.38M

---16.63M

---11.79M

---11.05M

---15.09M

Net income from continuing operations

38.16%-20.20M

19.31%-20.92M

31.22%-20.28M

-22.91%-26.10M

-50.61%-32.66M

-82.73%-25.92M

-46.65%-29.49M

-58.00%-21.24M

-16.21%-21.68M

2.68%-14.19M

-17.90%-20.11M

11.24%-13.44M

-49.24%-18.66M

---14.58M

---17.05M

---15.14M

---12.50M

Operating gains losses

-69.46%153.00K

-70.63%153.00K

-69.94%153.00K

-71.37%142.00K

5.25%501.00K

6.33%521.00K

10.65%509.00K

11.19%496.00K

6.50%476.00K

10.11%490.00K

34.50%460.00K

26.98%446.06K

6568.70%446.94K

--445.00K

--342.00K

--351.30K

--6.70K

Other non-cash items

2825.00%351.00K

1795.65%390.00K

26.30%437.00K

18.58%402.00K

-96.27%12.00K

-106.89%-23.00K

14.19%346.00K

9.95%339.00K

0.41%322.00K

12.46%334.00K

4.84%303.00K

5.95%308.33K

--320.67K

--297.00K

--289.00K

--291.00K

----

Change in working capital

-162.51%-4.21M

62.56%-2.40M

-269.35%-12.51M

40.56%-1.34M

67.91%6.73M

-376.00%-6.41M

62.14%7.38M

-93.81%-2.26M

813.20%4.01M

55.36%-1.35M

1.36%4.55M

-136.52%-1.16M

80.45%-561.98K

---3.02M

--4.49M

--3.19M

---2.87M

-Change in prepaid expenses

-209.12%-1.12M

24.13%-1.58M

892.59%2.14M

-355.98%-2.20M

-80.10%-362.00K

-397.99%-2.08M

-513.64%-270.00K

556.90%861.00K

-138.33%-201.00K

184.40%698.00K

-109.95%-44.00K

-246.47%-188.44K

132.12%524.44K

---827.00K

--442.00K

--128.65K

---1.63M

-Change in other current assets

----

100.00%0.00

----

---1.00K

--3.00K

----

-Change in other current liabilities

122.22%2.00K

-700.00%-8.00K

--8.00K

-100.00%0.00

---9.00K

---1.00K

100.00%0.00

38.30%11.00K

100.00%0.00

-155.56%-5.00K

1629.13%7.95K

82.88%-7.95K

---15.00K

--9.00K

--460.00

---46.46K

Cash from non-recurring investing activities

Cash from operating activities

2.63%-21.14M

29.11%-20.08M

-65.94%-29.55M

-35.07%-27.22M

-46.07%-21.72M

-102.60%-28.33M

-27.65%-17.81M

-52.77%-20.15M

19.09%-14.87M

15.91%-13.98M

-18.32%-13.95M

-19.37%-13.19M

-21.73%-18.38M

---16.63M

---11.79M

---11.05M

---15.09M

Investing cash flow

Net cash from continuing investing activities

--35.00K

100.00%0.00

248.19%289.00K

-50.46%108.00K

----

-117.81%-13.00K

56.60%83.00K

458.97%218.00K

--193.00K

-31.78%73.00K

-86.75%53.00K

-82.30%39.00K

-100.00%0.00

--107.00K

--400.00K

--220.38K

--173.63K

Capital expenditures

--35.00K

--0.00

248.19%289.00K

-50.46%108.00K

----

-100.00%0.00

56.60%83.00K

458.97%218.00K

--193.00K

-31.78%73.00K

-86.75%53.00K

-82.30%39.00K

-100.00%0.00

--107.00K

--400.00K

--220.38K

--173.63K

Net cash flow from disposal of fixed assets

--35.00K

--0.00

248.19%289.00K

-49.30%108.00K

----

-100.00%0.00

2666.67%83.00K

446.15%213.00K

--185.00K

192.00%73.00K

-99.16%3.00K

-66.77%39.00K

-100.00%0.00

--25.00K

--356.00K

--117.38K

--173.63K

Net cash flow from intangible asset transactions

----

---13.00K

-100.00%0.00

--5.00K

--8.00K

-100.00%0.00

13.64%50.00K

-100.00%0.00

--0.00

--82.00K

--44.00K

--103.00K

----

Net cash flow from investment products

76.25%27.50M

-8.65%-101.69M

--35.30M

---39.07M

--15.60M

---93.60M

----

Net cash flow from other investing activities

--0.00

----

Cash from non-current investing activities

Net cash flow from investing activities

76.03%27.46M

-8.66%-101.69M

42281.93%35.01M

-17869.72%-39.17M

8182.90%15.60M

-128095.89%-93.58M

-56.60%-83.00K

-458.97%-218.00K

---193.00K

31.78%-73.00K

86.75%-53.00K

82.30%-39.00K

100.00%0.00

---107.00K

---400.00K

---220.38K

---173.63K

Financing cash flow

Cash flow from continuous financing activities

22190.91%2.45M

148318.56%143.77M

172.22%52.00K

24972.16%72.96M

-99.99%11.00K

-100.10%-97.00K

-101.84%-72.00K

407.74%291.00K

91083.17%88.65M

123644.44%100.07M

11277.14%3.91M

-292.93%-94.56K

-138.06%-97.44K

---81.00K

---35.00K

--49.01K

--255.99K

Net cash flow from debt Issuance/repayment

23.90%-121.00K

-45.69%-169.00K

25.23%-83.00K

-64.86%-122.00K

-45.87%-159.00K

-10.48%-116.00K

-102.85%-111.00K

28.45%-74.00K

0.53%-109.00K

2.78%-105.00K

10913.89%3.89M

-444.33%-103.42K

---109.58K

---108.00K

---36.00K

---19.00K

--0.00

Net cash flow from common stock issuance/repurchase

-15.88%143.00K

3843825.00%153.75M

--101.00K

148246.30%80.00M

-99.81%170.00K

---4.00K

--0.00

---54.00K

--88.75M

----

Net cash flow from preferred stock issuance/repurchase

----

100.00%0.00

-100.00%0.00

--0.00

-100.00%0.00

---1.00K

--1.00K

----

--20.53K

Proceeds from stock option exercised by employees

--9.00K

8.70%25.00K

-12.82%34.00K

----

--23.00K

30.00%39.00K

4628.05%419.00K

-17.61%10.00K

-100.00%0.00

--30.00K

-87.07%8.86K

-94.84%12.14K

--28.00K

--0.00

--68.54K

--235.46K

Proceeds from issuance of warrants

--2.45M

----

Net cash flow from other financing activities

---25.00K

---9.83M

--0.00

---6.92M

----

--100.18M

---11.00K

----

---529.00

----

Net cash from non-recurrent financing activities

Net cash from financing activities

22190.91%2.45M

148318.56%143.77M

172.22%52.00K

24972.16%72.96M

-99.99%11.00K

-100.10%-97.00K

-101.84%-72.00K

407.74%291.00K

91083.17%88.65M

123644.44%100.07M

11277.14%3.91M

-292.93%-94.56K

-138.06%-97.44K

---81.00K

---35.00K

--49.01K

--255.99K

Net cash flow

Beginning cash balance

73.12%66.25M

-72.39%44.24M

-78.27%38.73M

-83.78%32.16M

-69.32%38.27M

314.13%160.27M

265.30%178.23M

219.26%198.31M

54.76%124.72M

-60.27%38.70M

-55.49%48.79M

-48.60%62.12M

-40.68%80.59M

--97.40M

--109.63M

--120.85M

--135.86M

Current period cash flow changes

243.62%8.77M

118.04%22.00M

130.71%5.52M

132.71%6.57M

-108.30%-6.11M

-241.84%-122.01M

-78.01%-17.96M

-50.69%-20.08M

498.39%73.59M

611.58%86.02M

17.46%-10.09M

-18.74%-13.32M

-23.05%-18.47M

---16.81M

---12.22M

---11.22M

---15.01M

Ending cash balance

133.25%75.02M

73.12%66.25M

-72.39%44.24M

-78.27%38.73M

-83.78%32.16M

-69.32%38.27M

314.13%160.27M

265.30%178.23M

219.26%198.31M

54.76%124.72M

-60.27%38.70M

-55.49%48.79M

-48.60%62.12M

--80.59M

--97.40M

--109.63M

--120.85M

Free cash flow

2.47%-21.18M

29.11%-20.08M

-66.78%-29.84M

-34.15%-27.33M

-44.20%-21.72M

-101.55%-28.33M

-27.76%-17.89M

-53.97%-20.37M

18.04%-15.06M

16.01%-14.05M

-14.87%-14.00M

-17.38%-13.23M

-20.35%-18.38M

---16.73M

---12.19M

---11.27M

---15.27M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Lexeo Therapeutics Inc Generate?



Lexeo Therapeutics Inc generated -98.56M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Lexeo Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Lexeo Therapeutics Inc's operating cash flow increased by -21.45% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Lexeo Therapeutics Inc Spend on Capital Expenditures?



Lexeo Therapeutics Inc spent 397.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Lexeo Therapeutics Inc's Financing Cash Flow Changed?



Lexeo Therapeutics Inc used 216.79M in financing activities in the latest quarter.

What is free cash flow and why does it matter for LXEO?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Lexeo Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -98.96M reflecting a -21.22% change from the previous year.